Eptifibatide Acetate Powder 98% Cas No.148031-34-9
Product source: Artificially synthesized cyclic heptapeptide
Content specification: ≥ 98%
CAS number: 148031-34-9
Detection method: HPLC
Active ingredient: cyclic heptapeptide
Product mesh: 80-120 mesh
Product Description: White to off white powder
Product Usage: Medical Applications
Product storage: -20 ° C vacuum freeze-drying storage
Shelf life: 24-36 months
Eptifibatide Acetate API Powder | Pharmaceutical Grade Raw Material
Xi'an Tihealth Biotechnology Co., Ltd. - High-Purity Synthetic Peptide
⚠️ PHARMACEUTICAL GRADE API: This product is intended for pharmaceutical manufacturing and clinical R&D. Xi'an Tihealth operates under strict GMP-aligned quality control systems to ensure batch consistency and low impurity levels for cardiovascular drug production.
Xi'an Tihealth specializes in producing high-purity Eptifibatide Acetate meeting stringent pharmaceutical standards. As a highly selective antagonist of platelet GPIIb/IIIa receptors, this synthetic heptapeptide (832 Da) is a key API for acute coronary syndrome (ACS) treatment and PCI adjuvant therapy. We utilize advanced synthesis technology to ensure HPLC purity ≥ 98.0%, providing a stable supply chain for global pharmaceutical manufacturers.
Technical Data Sheet (TDS) Profile
| Analytical Parameter | Specification & Standard |
|---|---|
| Purity (HPLC) | ≥ 98.0% |
| Molecular Weight | 832 Da |
| Structure | Synthetic Heptapeptide (Non-antibody) |
| Appearance | White to off-white powder |
| Application | ACS and PCI adjunctive therapy |
Clinical Utility & Advantages
- Mechanism: Rapidly inhibits platelet aggregation by reversibly blocking fibrinogen binding to GPIIb/IIIa receptors.
- Clinical Scope: ACS (Unstable Angina, NSTEMI) and PCI adjunctive treatment (thromboembolic complication prevention).
- Safety Profile: Clear synthetic structure, non-antibody type, no risk of immunogenicity.
- Efficiency: Rapid onset with peak effect within 5 minutes post-IV administration.
Frequently Asked Questions
Q1: What are the primary advantages of your Eptifibatide Acetate over antibodies?
Our product is a synthetic heptapeptide with a low molecular weight (832 Da), which carries zero risk of immunogenicity compared to large-molecule antibody drugs, ensuring a superior safety profile for cardiovascular patients.
Q2: Is this API suitable for acute clinical intervention?
Yes. The API demonstrates a rapid onset of action, with the peak effect achieved within 5 minutes after intravenous administration, making it an ideal choice for acute coronary syndrome and emergency PCI adjuvant scenarios.
Q3: How do you ensure the batch-to-batch consistency of this API?
We implement strict GMP-aligned quality control throughout the synthesis process. Every batch is validated by HPLC to ensure a consistent purity of ≥ 98.0%, meeting the stringent requirements of pharmaceutical-grade raw materials.
Hot Tags: Eptifibatide Acetate Powder 98% Cas No.148031-34-9, China Eptifibatide Acetate Powder 98% Cas No.148031-34-9 manufacturers, suppliers, factory, tranexamic powder
You Might Also Like
Send Inquiry